President Emmanuel Macron's speech on World Cancer Day organized by the National Cancer Institute (INCa) on February 4th confirms more than ever the need for early cancer detection.Imstar-Dx has been engaged in this struggle for more than 25 ye ...
IMSTAR received a Seal of Excellence from the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020, for its project CECAD: A novel Blood test by Cell imaging for Ea ...
With the additional set-up of 6 to 20 Pathfinder™ CTC Cell Reader-Analyzers, we strengthen our presence in China, and the recognition of our innovative technology in liquid biopsy accurate testing, allowing CTCs and CTMs counting and characterizatio ...
IMSTAR has installed Pathfinder™ Cellscan SreenTox, a robotized system for automated screening of genetic toxicology assays including micronucleus assay, comet assay, chromosome aberrations scoring, mitotic index measurement and H2AX foci detection ...
IA-based Solutions Quantitative Digital Pathology
Over 25 years of experience in Intelligent Software solutions, Imstar-Dx is a Spin-off of the CEA’s Nuclear Medicine Department, Life Sciences Division. Imstar-Dx is focused on cancer research and diagnosis since its inception.
© 2021 IMSTAR DX BUSINESS THEME.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
